Director/PDMR Shareholding

RNS Number : 8100V

Renalytix AI PLC

19 April 2021

 

Renalytix AI plc

Director/PDMR Shareholding

New York, 19 April 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announces that it has been advised of the transfer by James McCullough, the Company's Chief Executive Officer, of certain of the ordinary shares of £0.0025 each in the capital of the Company ("Ordinary Shares") owned by him to a new family trust, The McCullough 2020 Irrevocable Trust (the "Trust").

The transaction involves the gift of 255,440 Ordinary Shares to James McCullough and Michele Wiles as investment trustees of the Trust and the sale of 2,298,958 Ordinary Shares to James McCullough and Michele Wiles as investment trustees of the Trust.

Following completion of this transfer, James McCullough remains interested in 2,870,110 Ordinary Shares representing 3.98% of the current issued share capital. 2,554,398 are held via the Trust with the balance of 315,712 being held in James McCullough's name.

The information contained in this notification is disclosed in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. The notification form is set out below.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	James McCullough
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Renalytix AI plc
b)	Legal Entity Identifier	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.0025 each ISIN Code: GB00BYWL4Y04
b)	Nature of the transaction	Gift of shares to a trust for nil consideration Sale of shares to a trust
c)	Currency	N/A
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	255,440 Ordinary Shares
		US$6.68	2,298,958 Ordinary Shares
e)	Aggregated information - Aggregated volume - Price - Aggregated total - Aggregated volume - Price - Aggregated total	255,440 Nil Nil 2,298,958 $6.68 US$15,357,039.44
f)	Date of the transaction	18 April 2021
g)	Place of the transaction	Outside a trading venue

For further information, please contact:

Renalytix AI plc		www.renalytixai.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker   )		Tel: [phone]
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)		Tel: [phone]
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: [phone]  or    [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone]

About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally.    The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD).  Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer.    Every day, 13 patients in the United States die while waiting for a kidney transplant.

*    https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit  www.renalytixai.com  

 

END

 

 

DSHDKFBDDBKBPQD